Cargando…
Partial response of donafenib as the third-line therapy in metastatic colon cancer: A case report
RATIONALE: Colorectal cancer (CRC) is a digestive tumor with high morbidity and mortality rates. After second-line treatment failure, third-line treatment options are limited, and the objective response rate is low. These patients are expected to have a short survival time. Therefore, it is very imp...
Autores principales: | Yang, Yang, Zhu, Hong, Li, Qiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447981/ https://www.ncbi.nlm.nih.gov/pubmed/34664852 http://dx.doi.org/10.1097/MD.0000000000027204 |
Ejemplares similares
-
Donafenib treatment for hepatocellular carcinoma: A case report
por: Li, Qiaoqi, et al.
Publicado: (2021) -
A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy
por: Attademo, Laura, et al.
Publicado: (2018) -
The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022) -
Cronkhite-Canada syndrome associated with colon cancer metastatic to liver: A case report
por: Wang, Jing, et al.
Publicado: (2017) -
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
por: Lee, Victor H.F., et al.
Publicado: (2017)